Recovery

July 14, 2022 | Alcohol, Controlled Substances, Fact Sheets, Harm Reduction, Opioids, Prescription Drugs, Public Health, Recovery, Substance Abuse, Treatments

Recovery residences provide a sober, safe, and healthy living environment that promotes recovery from alcohol and other drug use and associated problems. These residences are commonly referred to by a number of names, including sober living houses, sober living environments, and recovery homes, and their primary purpose is to provide a home-like environment for individuals in recovery from substance use disorder to help sustain that recovery....

June 22, 2022 | Controlled Substances, Opioids, Prescription Drugs, Public Health, Recovery, Reports & Studies, Substance Abuse, Treatments

The COVID-19 pandemic created an unprecedented public health emergency throughout the world, prompting providers to turn to telehealth to provide necessary health care to patients at a distance. This paper analyzes the current state of telehealth services at the federal and state levels, as well as the benefits and limitations of telehealth technology use. It also offers public policy recommendations to improve telehealth services in the United States....

May 19, 2022 | Controlled Substances, Harm Reduction, Innovative Initiatives, Law Enforcement, Opioids, Prescription Drugs, Public Health, Recovery, Substance Abuse, Treatments

The restaurant industry has been particularly impacted by the opioid epidemic with, for example, ten percent of food service workers dying from opioid overdoses in the State of Delaware.[1] This sobering statistic prompted the Delaware Division of Public Health (DPH) to launch the Restaurant Accolade Program (the Program), which trains all restaurant staff and owners in the state on how to identify, respond to, and reverse an opioid overdose and helps food establishments draft policies that support employees and patrons with substance use disorders (SUDs). The Office of Health Crisis Response (OCHR) within DPH conducts the training and education....

March 28, 2022 | Controlled Substances, Criminal Justice, Drug Courts, Law Enforcement, Opioids, Prescription Drugs, Public Health, Public Safety, Recovery, Reports & Studies, Substance Abuse, Synthetic Drugs

In September 2021, Georgetown University Law Center convened an Opioid Litigation Summit. This convening brought together numerous experts to discuss legal, administrative, and programmatic strategies needed to optimize the impact of proceeds from the opioid litigation. The themes described in this brief emerged from the Summit and can be applied to the opioid litigation as well as future mass tort litigation to address public health crises....

March 3, 2022 | Controlled Substances, Harm Reduction, Innovative Initiatives, Law Enforcement, Opioids, Prescription Drugs, Public Health, Recovery, Substance Abuse, Treatments

When Pennsylvania Attorney General Josh Shapiro learned that approximately 15 citizens of the Commonwealth of Pennsylvania die each day from an overdose, he took action. As a result, in May of 2018, he launched the Law Enforcement Treatment Initiative (LETI) to connect individuals suffering with a substance use disorder (SUD) to treatment resources....

March 2, 2022 | Controlled Substances, Criminal Justice, Drug Courts, First Responders, Harm Reduction, Law Enforcement, Model Laws, Public Health, Public Safety, Recovery, Substance Abuse, Treatments

The Law Enforcement and Other First Responder Deflection (Act), drafted in collaboration with the Police, Treatment, and Community Collaborative (PTACC), encourages the use and establishment of deflection programs on the state level. Specifically, the model act (1) authorizes law enforcement and other first responders to develop and implement collaborative deflection programs that provide proactive policing to assist individuals who are at risk; (2) offers pathways to treatment, recovery services, housing, medication for addiction treatment, whole family services, and other needed supports; (3) requires deflection programs to have certain threshold elements to be eligible to receive grant funding; and (4) requires agencies establishing deflection programs to develop comprehensive memoranda of understanding in conjunction with, and agreed to by, all deflection program partners....

March 2, 2022 | Controlled Substances, Criminal Justice, Drug Courts, Law Enforcement, Opioids, Public Health, Recovery, Reports & Studies, Substance Abuse, Synthetic Drugs

“Stigma” is defined as stereotypes or negative views attributed to a person or groups of people whose characteristics or behaviors are viewed as different from, or inferior to, societal norms. Surveys of public attitudes about various stigmatizing conditions indicate that individuals with a substance use disorder are viewed more negatively than individuals with a mental disorder. This report, released in collaboration with Rulo Strategies LLC, explores efforts to reduce stigma towards individuals with a substance use disorder in public safety and justice settings....

February 8, 2022 | Controlled Substances, Criminal Justice, Harm Reduction, Medication Assisted Treatment (MAT), Naloxone, Opioids, Prescription Drugs, Public Health, Recovery, Substance Abuse, Toolkits, Treatments

The 2022 AMA-Manatt Toolkit builds on a previously published roadmap by providing actionable resources that states can use to take specific actions in six policy areas: (1) Increase access to evidence-based treatments to help patients with a substance use disorder (SUD); (2) Ensure access to addiction medicine, psychiatry, and other trained physicians; (3) Enforce mental health and substance use disorder (SUD) parity laws; (4) Improve access to multidisciplinary, multimodal care for patients with pain; (5) Expand harm reduction efforts to reduce death and disease; and (6) Improve monitoring and evaluation....

December 10, 2021 | Controlled Substances, Criminal Justice, Harm Reduction, Opioids, Prescription Drugs, Public Health, Recovery, Reports & Studies, Substance Abuse, Treatments

The Bloomberg School of Public Health at Johns Hopkins University recently released a three-part report about the multi-district opioid litigation that has been making its way through the court system for many years. Part 1 of the trilogy, focuses on a series of principles governing the use of the settlement funds: (1) spending money to save lives; (2) using evidence to guide spending; (3) investing in youth prevention; (4) focusing on racial equity; and (5) developing a fair and transparent process for deciding where to spend the funding....

November 16, 2021 | Controlled Substances, First Responders, Harm Reduction, Model Laws, Naloxone, Opioid Antagonists, Opioids, Public Health, Public Safety, Recovery, Substance Abuse, Treatments

LAPPA’s Model Expanded Access to Emergency Opioid Antagonists Act provides state officials with the means to increase the ability of their citizens to access and use life-saving emergency opioid antagonists. The Centers for Disease Control and Prevention estimates that over 934,000 Americans died from a fatal overdose involving an opioid between 1999 and 2020. Opioid antagonists, such as naloxone, can be used during emergencies to reverse opioid overdoses and are effective in preventing fatal drug overdoses. This Act: (1) enables all citizens to access emergency opioid antagonists; (2) encourages citizens to obtain emergency opioid antagonists; (3) grants immunity to individuals who administer opioid antagonists; (4) requires physicians to co-prescribe an emergency opioid antagonist when prescribing an opioid to someone; (5) ensures that health insurance covers emergency opioid antagonists, like naloxone; (6) prohibits discriminatory life and health insurance practices related to the possession of emergency opioid antagonists; (7) provides increased access to opioid antagonists in educational institutions and correctional settings; (8) establishes a pilot program to increase bystander access to emergency opioid antagonists; and (9) promotes initiatives that educate citizens on the life-saving potential of emergency opioid antagonists....